|
1. BIOLOGIE
|
|
|
|
2. ETIOLOGIE
|
|
|
CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer [CNIO]
|
|
|
|
|
|
The finding is based on PROREPAIR-B, a prospective multi-centre observational cohort study that followed up more than 400 patients with metastatic prostate cancer. The study aimed to identify genetic markers associated with prostate cancer progression and patient treatment responses. High-risk prostate cancer patients with BRCA2 mutations are likely to suffer from aggressive cancer that develops resistance to standard treatment.
|
|
|
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
|
4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS
|
|
|
AI approach outperformed human experts in identifying cervical precancer [NCI]
|
|
|
|
|
|
To create the algorithm, the research team used more than 60,000 cervical images from an NCI archive of photos collected during a cervical cancer screening study that was carried out in Costa Rica in the 1990s. More than 9,400 women participated in that population study, with follow up that lasted up to 18 years.
|
|
|
|
|
|
|
5. TRAITEMENTS
|
|
|
|
5.12.7 IMMUNOTHÉRAPIES - VACCINS
|
|
|
|
Brain Cancer Patient Is First to Get Untested Treatment Under Trump-Backed Law [Bloomberg]
|
|
|
|
|
|
The treatment, called Gliovac, is a vaccine crafted from the patient’s own cells and tissue taken from other patients with glioblastoma -- the same aggressive tumor that killed John McCain a year after his diagnosis. It’s being provided to the man, who has chosen to remain anonymous for now, by Epitopoietic Research Corp., or ERC, a closely-held Belgian company that is testing it in human trials.
|
|
|
|
|
|
|
5.2 PHARMA
|
|
|
|
|
Betting on allosteric mutations driving cancer, Black Diamond raises $85M in fresh round [EndPoints]
|
|
|
|
|
|
As increasing genomic profiling of cancer patients identifies clusters of uncharacterized genomic alterations, the biotech’s technology is designed to isolate “druggable mutation baskets” to create precision medicines. The company currently has two programs: allosteric HER2 and EGFR driver mutations that occur across a range of tissue type tumors, and other undisclosed programs brewing in its pipeline.
|
|
|
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
Eli Lilly plots 250 job cuts in €100M revamp of French plant [Fierce Pharma]
|
|
|
|
|
|
The cuts follow moves by Boehringer and Sanofi to trim down in the country. Last month, Sanofi told Reuters it was planning 670 layoffs through 2020, also through "voluntary departures." And a few days later, BI's president in France told FiercePharma his company plans to trim 327 jobs in the country but add 32 positions, for a net loss of 295 employees.
|
|
|
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.12 ETHIQUE
|
|
|
|
6.5 MÉDECINES ALTERNATIVES/COMPLÉMENTAIRES
|
|
|
|
6.7.1 IA/BIOINFORMATIQUE
|
|
|